X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Auxora (zegocractin) is a potent and selective small molecule inhibitor of Orai1-containing CRAC channels, to be evaluated in a Phase 2 trial in acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF).
Lead Product(s): Zegocractin
Therapeutic Area: Nephrology Product Name: Auxora
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2024
Details:
The net proceeds will be used for the clinical development of the Auxora (zegocractin), which is a small molecule CRAC channel inhibitor and are also planning for Phase 2 for the treatment of acute kidney injury.
Lead Product(s): Zegocractin
Therapeutic Area: Nephrology Product Name: Auxora
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Deerfield Management
Deal Size: $55.0 million Upfront Cash: $20.4 million
Deal Type: Private Placement January 22, 2024
Details:
Auxora (zegocractin) is a potent and selective small molecule inhibitor of Orai1-containing calcium release-activated calcium (CRAC) channels that is being developed for use in patients with inflammatory illnesses.
Lead Product(s): Zegocractin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Auxora
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2023
Details:
CM5480 is a selective oral CRAC channel inhibitor and restored the expression of SOCE-associated regulatory factor in acinar cells, which being developed for Chronic Pancreatitis (CP).
Lead Product(s): CM5480
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM5480
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2023
Details:
The combined company will focus on developing Auxora (zegocractin), an intravenous-formulated, small molecule CRAC channel inhibitor, to treat inflammatory diseases, such as AP, AAP which is a toxicity caused by asparaginase treatment for pediatric ALL, AKI, ALI andARDS.
Lead Product(s): Zegocractin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Auxora
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Graybug Vision Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 20, 2023
Details:
The proceeds will be used for the advancement of Auxora (zegocractin), an intravenous-formulated, small molecule CRAC channel inhibitor, to treat inflammatory diseases, such as AP, AAP which is a toxicity caused by asparaginase treatment for pediatric ALL, AKI, ALI andARDS.
Lead Product(s): Zegocractin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Auxora
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $10.3 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 20, 2023
Details:
The combined company will focus on further developing CalciMedica’s lead product candidate Auxora, a proprietary, intravenous-formulated, small molecule calcium-release activated calcium (CRAC) channel inhibitor, to treat life-threatening inflammatory diseases.
Lead Product(s): Zegocractin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM4620
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CalciMedica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger November 21, 2022
Details:
GB-102 is a microparticle formulation of a pan-VEGF inhibitor, sunitinib, for the treatment of wet age-related macular degeneration designed for a twice-per-year intravitreal injection. GB-102 has the potential to also benefit patients with diabetic retinopathy.
Lead Product(s): Sunitinib
Therapeutic Area: Ophthalmology Product Name: GB-102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
Details:
GB-401 is a first-in-class implant formulation containing a novel prodrug of timolol for the treatment of primary open-angle glaucoma (POAG) designed for a twice-per-year intravitreal injection with a proprietary applicator.
Lead Product(s): GB-401
Therapeutic Area: Ophthalmology Product Name: GB-401
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
Preclinical studies in a canine model of MPS1 for GB-501 an AAV gene therapy, demonstrated complete and sustained clearing of the cornea in all dogs, regardless of disease severity, in less than a month following a single intrastromal injection.
Lead Product(s): GB-501
Therapeutic Area: Genetic Disease Product Name: GB-501
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
